Used in research as a selective inhibitor of AXL kinase, a receptor tyrosine kinase implicated in cancer progression and metastasis. Shows potential in oncology studies, particularly in models of acute myeloid leukemia and solid tumors, where AXL signaling contributes to drug resistance and immune evasion. Investigated for its ability to enhance the efficacy of other anticancer agents, including chemotherapy and immune checkpoint inhibitors, by modulating tumor microenvironment and suppressing survival pathways in malignant cells. Currently in preclinical development, serving as a tool compound to explore AXL-dependent signaling mechanisms and therapeutic strategies.